Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
- Empagliflozin Benefits for the Newly Diagnosed Type 2 Patient
- The Impact of Glycated Albumin in Diabetes Management and Diabetic Nephropathy
- Expanding the Role of Canagliflozin
- Improving Glycemic Control Through Resurfacing of the Duodenum
- The Role of Buprenorphine in Diabetic Neuropathic Pain
- Missing the Point
- Guest Writer David Kliff on the news from EASD
Letter from the Editor
The standard treatment for uncontrolled uterine bleeding has been emergency care where a woman undergoes transfusion dilatation curettage and then a hysterectomy. This is a severe procedure with a long recovery time and long-lasting complications. Over the past few years, a lot of women have been treated with endometrialhydrothermal ablation, a much less invasive procedure with a much quicker healing time.
The current hydrothermal technique (HTA Boston Scientific, Natick, MA), consists of saline being placed inside the endometrial cavity, and computer control is used to guard against any fluid leakage. The fluid is then heated to 90°C and monitored for 10 minutes to remove the fibroids and smooth the surface of the endometrium. This procedure has lowered the emergency procedures needed and has had a real impact on quality of life in hundreds of women.
Now there is research showing that it may be possible to treat diabetes in a similar manner. Duodenal mucosal resurfacing (DMR) is a novel, minimally invasive, catheter-based upper endoscopic procedure consisting of hydrothermal ablation of the duodenal mucosa that seems to have a positive effect on glucose levels and diabetes. Check out our news item #4 by Pablo A. Marrero-Núñez, Doctor of Pharmacy Candidate, University of South Florida College of Pharmacy, and learn about the procedure that may work as well as bypass surgery for controlling diabetes.
*****************************
We can make a difference!
*****************************
Dave Joffe, Editor-in-chief
Newsflash: FDA Approves Invokamet XR for Treatment of Adults With Type-2 Diabetes
This Week's Survey
When Lilly’s new Bio-Similar insulin for Lantus becomes available for maybe 20% less, will you let your patients know? Follow the link to share your opinion!
Tool for Your Practice: Drugs that Can Affect Blood Glucose
Knowing the drugs that can affect blood glucose levels is essential in properly caring for your diabetes patients. Some medicines raise blood sugar in patients while others might lower their levels. However, not all drugs affect patients the same way.
Take a look at the 390 drugs that can affect blood glucose.
Test Your Knowledge
Did You Know- Intensified Treatment Should Begin with Signs of Microalbuminuria
Type 2 patients who received intensified treatment at first signs of microalbuminuria survived almost 8 years longer than those who did not. Danish researchers used a cohort of 160 type 2 diabetes patients with microalbuminuria and found those in the intensive therapy group had 8.1 years longer median time to first cardiovascular event and a reduced risk for all microvascular complications, except for peripheral neuropathy, compared with the conventional therapy group. According to this study published online in Diabetologia, which included patients with type 2 diabetes and microalbuminuria, showed that early, intensified intervention in type 2 diabetes patients with microalbuminuria increased their lifespan, with patients more likely free from severe complications, according to the published study. Participants were randomly assigned to conventional therapy or an intensified, multifactorial treatment that included behavioral and pharmacological intervention. Of those 160 patients, 38 intensive-therapy patients and 55 conventional-therapy patients died during follow-up of 21.2 years (hazard ratio, 0.55). The average survival was a median of 7.9 years longer for patients in the intensive-therapy group versus the conventional-therapy group. The median time to first cardiovascular event was 8.1 years longer in the intensive-therapy group, and the risk for all microvascular complications was decreased in the intensive-therapy group with the exception of peripheral neuropathy. In conclusion, from the results of the study, they found that intensified, multifactorial treatment of type 2 diabetes with microalbuminuria for 7.8 years compared with conventional treatment increased median life length by 7.9 years over 21.2 years of follow-up, and that these gained years were matched by years free from cardiovascular complications. — First online at Diabetologia August 16, 2016
A1C reductions seen in therapy combined with metformin
Can glycated albumin provide better positive predictive value than A1c in incidence of diabetic nephropathy?
Canagliflozin can decrease blood sugar and provide control, but what other metabolic effects can it provide?
What benefits can be obtained from duodenal mucosal resurfacing?
Study finds improvement in pain relief and sleep patterns
Guest Writer: David Kliff, Diabetic Investor
Friend of Diabetes in Control and frequent guest author David Kliff, Diabetic Investor, shared his views on some of the news coming out of EASD. As always, his ideas are thought-provoking. We reached out to some of our Advisory Board members to get their responses to David’s piece, and they provided additional strong viewpoints for your consideration.
Quote of the Week!
‘We must not allow other people’s limited perceptions to define us.’
…Virginia Satir
Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletter:
Christian Gill, University of Rhode Island
Pablo A. Marrero-Núñez, USF College of Pharmacy
Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
810 Bear Tavern Road Suite 102
Ewing, NJ, 08628
USA
www.diabetesincontrol.com